Caplin Point Laboratories Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1941.95 -9.35 (-0.48%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1925
Today’s High
1994.3
52 Week Low
1179.95
52 Week High
2175
1946.00 -6.15 (-0.32%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1923.05
Today’s High
1973.75
52 Week Low
1178
52 Week High
2176.75
Key Metrics
- Market Cap (In Cr) 14838.62
- Beta 0.66
- Div. Yield (%) 0.13
- P/B 6.4
- TTM P/E 29.21
- Peg Ratio 1.28
- Sector P/E 31.15
- D/E 0
- Open Price 1994.3
- Prev Close 1951.3
Caplin Point Laboratories Analysis
Price Analysis
-
1 Week-2.98%
-
3 Months9.79%
-
6 Month51.25%
-
YTD43.95%
-
1 Year53.76%
Risk Meter
- 48% Low risk
- 48% Moderate risk
- 48% Balanced Risk
- 48% High risk
- 48% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 2
- 2
- 2
- 2
Caplin Point Laboratories News
Caplin Point stock rises 15% as subsidiary clears Brazilian regulator's inspection
2 min read . 19 Aug 2024Buy or sell: Vaishali Parekh recommends three stocks to buy today — February 14
2 min read . 14 Feb 2024Bharat Electronics, Caplin Point among top stock picks by HDFC Securities
3 min read . 03 Jan 2024Caplin Point Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1694.1
- Selling/ General/ Admin Expenses Total
- 143.59
- Depreciation/ Amortization
- 53.44
- Other Operating Expenses Total
- 274.89
- Total Operating Expense
- 1196.1
- Operating Income
- 498
- Net Income Before Taxes
- 564.43
- Net Income
- 457.09
- Diluted Normalized EPS
- 59.9
- Period
- 2024
- Total Assets
- 2697.38
- Total Liabilities
- 381.68
- Total Equity
- 2315.7
- Tangible Book Valueper Share Common Eq
- 303.28
- Period
- 2024
- Cashfrom Operating Activities
- 318.39
- Cashfrom Investing Activities
- -312.63
- Cashfrom Financing Activities
- -38.07
- Net Changein Cash
- -31.45
- Period
- 2023
- Total Revenue
- 1466.73
- Selling/ General/ Admin Expenses Total
- 266.98
- Depreciation/ Amortization
- 44.99
- Total Operating Expense
- 1069.96
- Operating Income
- 396.77
- Net Income Before Taxes
- 451.35
- Net Income
- 376.26
- Diluted Normalized EPS
- 49.22
- Period
- 2023
- Total Assets
- 2191.4
- Total Liabilities
- 310.92
- Total Equity
- 1880.48
- Tangible Book Valueper Share Common Eq
- 246.28
- Period
- 2023
- Cashfrom Operating Activities
- 271.37
- Cashfrom Investing Activities
- -217.58
- Cashfrom Financing Activities
- -28.17
- Net Changein Cash
- 26.8
- Period
- 2022
- Total Revenue
- 1269.41
- Selling/ General/ Admin Expenses Total
- 233.31
- Depreciation/ Amortization
- 46.9
- Total Operating Expense
- 921.33
- Operating Income
- 348.08
- Net Income Before Taxes
- 385.82
- Net Income
- 299.84
- Diluted Normalized EPS
- 39.25
- Period
- 2022
- Total Assets
- 1736.32
- Total Liabilities
- 252.39
- Total Equity
- 1483.93
- Tangible Book Valueper Share Common Eq
- 194.37
- Period
- 2022
- Cashfrom Operating Activities
- 336.75
- Cashfrom Investing Activities
- -270.94
- Cashfrom Financing Activities
- -40.71
- Net Changein Cash
- 25.01
- Period
- 2021
- Total Revenue
- 1061.29
- Selling/ General/ Admin Expenses Total
- 186.89
- Depreciation/ Amortization
- 36.97
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 769.02
- Operating Income
- 292.27
- Net Income Before Taxes
- 313.62
- Net Income
- 242.27
- Diluted Normalized EPS
- 31.81
- Period
- 2021
- Total Assets
- 1363.61
- Total Liabilities
- 177.79
- Total Equity
- 1185.82
- Tangible Book Valueper Share Common Eq
- 155.8
- Period
- 2021
- Cashfrom Operating Activities
- 265.77
- Cashfrom Investing Activities
- -5.36
- Cashfrom Financing Activities
- -23.98
- Net Changein Cash
- 236.2
- Period
- 2020
- Total Revenue
- 863.2
- Selling/ General/ Admin Expenses Total
- 118.82
- Depreciation/ Amortization
- 31.62
- Total Operating Expense
- 634.75
- Operating Income
- 228.45
- Net Income Before Taxes
- 269.46
- Net Income
- 215.01
- Diluted Normalized EPS
- 28.42
- Period
- 2020
- Total Assets
- 1125.76
- Total Liabilities
- 177.84
- Total Equity
- 947.91
- Tangible Book Valueper Share Common Eq
- 124.64
- Period
- 2020
- Cashfrom Operating Activities
- 44.68
- Cashfrom Investing Activities
- -54.5
- Cashfrom Financing Activities
- 79.77
- Net Changein Cash
- 70.11
- Period
- 2019
- Total Revenue
- 648.69
- Selling/ General/ Admin Expenses Total
- 82.64
- Depreciation/ Amortization
- 23.42
- Other Operating Expenses Total
- 2.21
- Total Operating Expense
- 440.78
- Operating Income
- 207.91
- Net Income Before Taxes
- 226.88
- Net Income
- 176.57
- Diluted Normalized EPS
- 23.23
- Period
- 2019
- Total Assets
- 742.52
- Total Liabilities
- 109.61
- Total Equity
- 632.91
- Tangible Book Valueper Share Common Eq
- 83.41
- Period
- 2019
- Cashfrom Operating Activities
- 83.42
- Cashfrom Investing Activities
- -100.46
- Cashfrom Financing Activities
- 89.79
- Net Changein Cash
- 73.48
- Period
- 2018
- Total Revenue
- 539.84
- Selling/ General/ Admin Expenses Total
- 68.55
- Depreciation/ Amortization
- 18.99
- Other Operating Expenses Total
- 2.23
- Total Operating Expense
- 364.07
- Operating Income
- 175.77
- Net Income Before Taxes
- 188.38
- Net Income
- 144.79
- Diluted Normalized EPS
- 19.16
- Period
- 2018
- Total Assets
- 500.45
- Total Liabilities
- 136.62
- Total Equity
- 363.83
- Tangible Book Valueper Share Common Eq
- 47.85
- Period
- 2018
- Cashfrom Operating Activities
- 66.48
- Cashfrom Investing Activities
- -69.02
- Cashfrom Financing Activities
- -11.6
- Net Changein Cash
- -14.14
- Period
- 2024-09-30
- Total Revenue
- 483.1
- Selling/ General/ Admin Expenses Total
- 44.29
- Depreciation/ Amortization
- 16.76
- Other Operating Expenses Total
- 85.23
- Total Operating Expense
- 335.1
- Operating Income
- 148
- Net Income Before Taxes
- 168.46
- Net Income
- 130.8
- Diluted Normalized EPS
- 17.12
- Period
- 2024-09-30
- Total Assets
- 2924.22
- Total Liabilities
- 381.69
- Total Equity
- 2542.53
- Tangible Book Valueper Share Common Eq
- 333.01
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 185.82
- Cashfrom Investing Activities
- -129.95
- Cashfrom Financing Activities
- -18.88
- Net Changein Cash
- 38.14
- Period
- 2024-06-30
- Total Revenue
- 458.96
- Selling/ General/ Admin Expenses Total
- 40.15
- Depreciation/ Amortization
- 15.96
- Other Operating Expenses Total
- 81.52
- Total Operating Expense
- 323.11
- Operating Income
- 135.85
- Net Income Before Taxes
- 154.38
- Net Income
- 123.98
- Diluted Normalized EPS
- 16.32
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 453.22
- Selling/ General/ Admin Expenses Total
- 36.77
- Depreciation/ Amortization
- 16.4
- Other Operating Expenses Total
- 79.85
- Total Operating Expense
- 324.39
- Operating Income
- 128.83
- Net Income Before Taxes
- 146.03
- Net Income
- 121.59
- Diluted Normalized EPS
- 15.9
- Period
- 2024-03-31
- Total Assets
- 2697.38
- Total Liabilities
- 381.68
- Total Equity
- 2315.7
- Tangible Book Valueper Share Common Eq
- 303.28
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 318.39
- Cashfrom Investing Activities
- -312.63
- Cashfrom Financing Activities
- -38.07
- Net Changein Cash
- -31.45
- Period
- 2023-12-31
- Total Revenue
- 435.5
- Selling/ General/ Admin Expenses Total
- 36.67
- Depreciation/ Amortization
- 13.9
- Other Operating Expenses Total
- 66.44
- Total Operating Expense
- 307.12
- Operating Income
- 128.38
- Net Income Before Taxes
- 145.41
- Net Income
- 117.2
- Diluted Normalized EPS
- 15.39
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 410.06
- Selling/ General/ Admin Expenses Total
- 35.08
- Depreciation/ Amortization
- 11.76
- Other Operating Expenses Total
- 73.48
- Total Operating Expense
- 284.42
- Operating Income
- 125.64
- Net Income Before Taxes
- 146
- Net Income
- 114.87
- Diluted Normalized EPS
- 15.06
- Period
- 2023-09-30
- Total Assets
- 2412.84
- Total Liabilities
- 339.23
- Total Equity
- 2073.61
- Tangible Book Valueper Share Common Eq
- 271.76
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 129.43
- Cashfrom Investing Activities
- -153.21
- Cashfrom Financing Activities
- -17.15
- Net Changein Cash
- -39.66
- Period
- 2023-06-30
- Total Revenue
- 395.32
- Selling/ General/ Admin Expenses Total
- 35.07
- Depreciation/ Amortization
- 11.38
- Other Operating Expenses Total
- 55.12
- Total Operating Expense
- 280.17
- Operating Income
- 115.15
- Net Income Before Taxes
- 126.99
- Net Income
- 103.43
- Diluted Normalized EPS
- 13.55
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 389.28
- Selling/ General/ Admin Expenses Total
- 36
- Depreciation/ Amortization
- 11.13
- Other Operating Expenses Total
- 52.75
- Total Operating Expense
- 276.48
- Operating Income
- 112.8
- Net Income Before Taxes
- 124.05
- Net Income
- 102.11
- Diluted Normalized EPS
- 13.33
- Period
- 2023-03-31
- Total Assets
- 2191.4
- Total Liabilities
- 310.92
- Total Equity
- 1880.48
- Tangible Book Valueper Share Common Eq
- 246.28
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 271.37
- Cashfrom Investing Activities
- -217.58
- Cashfrom Financing Activities
- -28.17
- Net Changein Cash
- 26.8
- Period
- 2022-12-31
- Total Revenue
- 372.07
- Selling/ General/ Admin Expenses Total
- 34.54
- Depreciation/ Amortization
- 11.43
- Other Operating Expenses Total
- 64.26
- Total Operating Expense
- 274.13
- Operating Income
- 97.94
- Net Income Before Taxes
- 111.74
- Net Income
- 97.48
- Diluted Normalized EPS
- 12.75
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Caplin Point Laboratories Technical
Moving Average
SMA
- 5 Day1982.15
- 10 Day2012.62
- 20 Day1954.79
- 50 Day1948.82
- 100 Day1780.72
- 300 Day1572.17
Caplin Point Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Eris Lifesciences
- 1370.85
- 6.45
- 0.47
- 1521.05
- 810.1
- 18647.44
- Jubilant Pharmova
- 1140
- 8.9
- 0.79
- 1309
- 408.6
- 18051.98
- Caplin Point Laboratories
- 1941.95
- -9.35
- -0.48
- 2175
- 1179.95
- 14747.51
- Sanofi India
- 6050
- -98.95
- -1.61
- 7593.6
- 4382.64
- 13933.53
- Marksans Pharma
- 309
- 3.15
- 1.03
- 328.35
- 126.05
- 14002.76
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Eris Lifesciences
- 47.3
- 7.2
- 20.71
- 24.96
- Jubilant Pharmova
- 120.43
- 3.29
- 6.15
- 5.13
- Caplin Point Laboratories
- 32.55
- 6.4
- 22.81
- 25.39
- Sanofi India
- 23.92
- 13.95
- 31.61
- 21.03
- Marksans Pharma
- 42.46
- 6.7
- 19.36
- 14.03
Caplin Point Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-Nov-24
- Quarterly Results
- 07-Aug-24
- Quarterly Results & Final Dividend
- 16-May-24
- Audited Results & Interim Dividend
- 09-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results, Final Dividend & A.G.M.
- 27-May-23
- Audited Results & Interim Dividend
- 24-May-23
- Audited Results & Interim Dividend
- 11-Feb-23
- Quarterly Results
- 12-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-24
- 07-Aug-24
- AGM
- 21-Sept-23
- 08-Aug-23
- AGM
- 28-Sept-21
- 05-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-Aug-24
- -
- 23-Sept-24
- 2.5
- 16-May-24
- 31-May-24
- 31-May-24
- 2.5
- 07-Aug-23
- -
- 14-Sept-23
- 2.5
- 29-May-23
- 09-Jun-23
- 09-Jun-23
- 2
- 29-May-23
- 09-Jun-23
- 09-Jun-23
- 2
- 05-Aug-22
- -
- 21-Sept-22
- 2
- 12-May-22
- 24-May-22
- 23-May-22
- 2
- 05-Aug-21
- -
- 20-Sept-21
- 1.5
- 06-May-21
- 19-May-21
- 18-May-21
- 1.5